Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.,Journal of Digestive Diseases

当前位置： X-MOL 学术 › J. Dig. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Journal of Digestive Diseases ( IF 3.5 ) Pub Date : 2020-08-06 , DOI: 10.1111/1751-2980.12911
Shou Wu Lee,Chun Fang Tung,Yen Chun Peng,Han Chung Lien,Chi Sen Chang

Transarterial chemoembolization (TACE) is the treatment modality for intermediate, or Barcelona Clinic Liver Cancer stage B, hepatocellular carcinoma (HCC), but its beneficial effect on outcomes is still unsatisfactory. This study aimed to assess the outcomes of combined TACE and sorafenib for patients with intermediate HCC.

更新日期：2020-08-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>